Description

Antiviral Drugs Market: By Drug Class (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Others), By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Geography –Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

Global Anti-Retroviral drugs market (Antiviral Drugs Market)

 

Retroviruses is a single stranded RNA containing virus with DNA intermediate. Retrovirus use enzyme, reverse transcriptase to copy their RNA into DNA of the host cell. The retrovirus integrates its viral DNA into DNA of the host cell, which allows the retrovirus to replicate. Retroviruses can cause different outcomes for the infected cell. Retroviruses are capable of inducing autoimmune, immunosuppressive, and neurological illnesses. Some retroviruses, such as the spumaviruses and lentiviruses are capable of directly killing cells.

 

Antiviral Drugs Market, Antiretroviral drugs market, AntiViral Therapeutics Market, Respiratory Antivirals Market, Antiretroviral Therapy Market

Antiretroviral Drugs Market: 2018-2024

 

Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases. Globally antiretroviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory procedures hampering the global antiretroviral drugs market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs.

 

Global antiretroviral drugs market is segmented based on drug class, route of administration, and distribution channel

 

Based on drug class, antiviral drugs market is classified into

  • Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
  • Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
  • Protease Inhibitors
  • Integrate Inhibitors
  • Fusion Inhibitors
  • Chemokine Receptor Inhibitors
  • Others

 

Based on route of administration, antiviral drugs market is classified into

  • Oral
  • Parenteral

 

Based on distribution channel, antiviral drugs market is classified into

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

 

Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share. In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb’s late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases. For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding.

 

Geographically global antiretroviral drugs market is segmented into five key regions Viz. North America, Europe, Asia- Pacific, Latin America, and Middle East & Africa. North America antiretroviral market is driven by introduction of combination therapies such as antiretroviral therapy dosages by key players in the region. Asia Pacific antiretroviral drugs market expected to be fastest growing due to developing healthcare infrastructure and increase in government and non-government organization initiatives creating awareness of retroviral diseases especially HIV/AIDS. Asia Pacific region has many generic drug manufacturing companies that are already have significant presence in global retroviral drugs in market. Middle East and Africa region is expected to be key region owing to availability of large pool of patients with retroviral diseases. However, poor healthcare infrastructure and lack of awareness related to retroviral diseases among healthcare professionals expected to hamper market revenue growth in the region.

 

Some of the players in the global antiretroviral drugs market are Abbott Laboratories (U.S.), AstraZeneca plc (U.K.), Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S), Gilead Sciences (U.S.), GlaxoSmithKline Plc (U.K.), and F. Hoffmann-La Roche AG (Switzerland) to name a few

 

  • In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline’s joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.

 

Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2018-2024
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario


Location

GEOGRAPHY

PBI Location Map

  1. Executive summary
  2. Global Antiretroviral Drugs Market Introduction

             2.1. Global Antiretroviral Drugs Market – Taxonomy

             2.2. Global Antiretroviral Drugs Market –Definitions

                           2.2.1. Drug Class

                           2.2.2. Route of Administration

                           2.2.3. Distribution Channel

  1. Global Antiretroviral Drugs Market Dynamics

             3.1. Drivers

             3.2. Restraints

             3.3. Opportunities/Unmet Needs of the Market

             3.4. Trends

             3.5. Global Antiretroviral Drugs Market Dynamics – Factors Impact Analysis

             3.6. Global Antiretroviral Drugs Market – Regulations

                          3.6.1. U.S

                          3.6.2. Europe

                          3.6.3. Japan

                          3.6.4. China

             3.7. Global Antiretroviral Drugs Market – Product Innovations

  1. Global Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

             4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

             4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

             4.3. Market Oppurtunity Analysis

  1. Global Antiretroviral Drugs Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024

             5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

                          5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          5.1.3. Market Opportunity Analysis

             5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

                          5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          5.2.3. Market Opportunity Analysis

             5.3. Protease Inhibitors

                          5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          5.3.3. Market Opportunity Analysis

             5.4. Integrate Inhibitors

                          5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          5.4.3. Market Opportunity Analysis

             5.5. Fusion Inhibitors

                          5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          5.5.3. Market Opportunity Analysis

             5.6. Chemokine Receptor Inhibitors

                          5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          5.6.3. Market Opportunity Analysis

             5.7. Others

                          5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          5.7.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024

             6.1. Parenteral

                          6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          6.1.3. Market Opportunity Analysis

             6.2. Oral

                          6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          6.2.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Distribution Channel , 2013 – 2017 and Forecast, 2018 – 2024

             7.1. Retail Pharmacies

                          7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis                         

                          7.1.3. Market Opportunity Analysis

             7.2. Hospital Pharmacies

                          7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          7.2.3. Market Opportunity Analysis

             7.3. Online Pharmacies

                          7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          7.3.3. Market Opportunity Analysis

             7.4. Others

                          7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          7.4.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024

             8.1. North America

                          8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          8.1.3. Market Opportunity Analysis

             8.2. Europe

                          8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis                         

                          8.2.3. Market Opportunity Analysis

             8.3. Asia-Pacific

                          8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          8.3.3. Market Opportunity Analysis

             8.4. Latin America

                          8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          8.4.3. Market Opportunity Analysis

             8.5. Middle East and Africa

                          8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

                          8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

                          8.5.3. Market Opportunity Analysis

             8.6. Global Antiretroviral Drugs Market – Opportunity Analysis Index, By Drug Class, Route of administration, Distribution Channel and Region, 2018 – 2024

  1. North America Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

             9.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                          9.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

                          9.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

                          9.1.3. Protease Inhibitors

                          9.1.4. Integrate Inhibitors

                          9.1.5. Fusion Inhibitors

                          9.1.6. Chemokine Receptor Inhibitors

                          9.1.7. Others

             9.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          9.2.1. Parenteral

                          9.2.2. Oral

                          9.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          9.3.1. Retail Pharmacies

                          9.3.2. Hospital Pharmacies

                          9.3.3. Online Pharmacies

                          9.3.4. Others

             9.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

                          9.4.1. U.S.

                          9.4.2. Canada

             9.5. North America Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

             9.6. North America Antiretroviral Drugs Market Dynamics – Trends

  1. Europe Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

             10.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                          10.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

                          10.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

                          10.1.3. Protease Inhibitors

                          10.1.4. Integrate Inhibitors

                          10.1.5. Fusion Inhibitors

                          10.1.6. Chemokine Receptor Inhibitors

                          10.1.7. Others

             10.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          10.2.1. Parenteral

                          10.2.2. Oral

                                       10.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          10.3.1. Retail Pharmacies

                          10.3.2. Hospital Pharmacies

                          10.3.3. Online Pharmacies

                          10.3.4. Others

             10.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          10.4.1. Germany

                          10.4.2. UK

                          10.4.3. France

                          10.4.4. Spain

                          10.4.5. Italy

                          10.4.6. Russia

                          10.4.7. Poland

                          10.4.8. Rest of Europe

             10.5. Europe Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

             10.6. Europe Antiretroviral Drugs Market Dynamics – Trends

  1. Asia-Pacific Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

             11.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                          11.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

                          11.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

                          11.1.3. Protease Inhibitors

                          11.1.4. Integrate Inhibitors

                          11.1.5. Fusion Inhibitors

                          11.1.6. Chemokine Receptor Inhibitors

                          11.1.7. Others

             11.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          11.2.1. Parenteral

                          11.2.2. Oral

             11.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          11.3.1. Retail Pharmacies

                          11.3.2. Hospital Pharmacies

                          11.3.3. Online Pharmacies

                          11.3.4. Others

             11.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

                          11.4.1. Japan

                          11.4.2. China

                          11.4.3. India

                          11.4.4. ASEAN

                          11.4.5. Australia & New Zealand

                          11.4.6. Rest of Asia-Pacific

             11.5. Asia-Pacific Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

             11.6. Europe Antiretroviral Drugs Market Dynamics – Trends

  1. Latin America Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

             12.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                          12.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

                          12.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

                          12.1.3. Protease Inhibitors

                          12.1.4. Integrate Inhibitors

                          12.1.5. Fusion Inhibitors

                          12.1.6. Chemokine Receptor Inhibitors

                          12.1.7. Others

             12.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          12.2.1. Parenteral

                          12.2.2. Oral

             12.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          12.3.1. Retail Pharmacies

                          12.3.2. Hospital Pharmacies

                          12.3.3. Online Pharmacies

                          12.3.4. Others

             12.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          12.4.1. Brazil

                          12.4.2. Mexico

                          12.4.3. Argentina

                          12.4.4. Venezuela

                          12.4.5. Rest of Latin America

             12.5. Latin America Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

             12.6. Latin America Antiretroviral Drugs Market Dynamics – Trends

  1. Middle East and Africa Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

             13.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                          13.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

                          13.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

                          13.1.3. Protease Inhibitors

                          13.1.4. Integrate Inhibitors

                          13.1.5. Fusion Inhibitors

                          13.1.6. Chemokine Receptor Inhibitors

                          13.1.7. Others

             13.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          13.2.1. Parenteral

                          13.2.2. Oral

             13.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          13.3.1. Retail Pharmacies

                          13.3.2. Hospital Pharmacies

                          13.3.3. Online Pharmacies

                          13.3.4. Others

             13.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

                          13.4.1. Brazil

                          13.4.2. Mexico

                          13.4.3. Argentina

                          13.4.4. Venezuela

                          13.4.5. Rest of Latin America

             13.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

                          13.5.1. Gulf Cooperation Council (GCC) Countries

                          13.5.2. Israel

                          13.5.3. South Africa

                          13.5.4. Rest of MEA

             13.6. MEA Antiretroviral Drugs Market – Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

             13.7. MEA Antiretroviral Drugs Market Dynamics – Trends

  1. Competition Landscape

             14.1. Strategic Dashboard of Top Market Players

             14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

                          14.2.1. Abbott Laboratories (U.S.)

                          14.2.2. AstraZeneca plc (U.K.)

                          14.2.3. Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S)

                          14.2.4. Gilead Sciences (U.S.)

                          14.2.5. GlaxoSmithKline Plc (U.K.)

                          14.2.6. F. Hoffmann-La Roche AG (Switzerland)

  1. Research Methodology
  2. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX